To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Fifth sitting)

"rose—..."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Fifth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Fifth sitting)

"The point is that that is not on the face of legislation. All the Select Committees do this work incredibly well, but they do not have to be told on the face of a Bill to do it. Parliament does it anyway, so I wonder why the amendment is necessary...."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Fifth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Sixth sitting)

"I have a lot of sympathy for what the hon. Member says, because clearly the more clarity a potential investor has when investing in the UK, the better. The only problem is that if the Government are in a position to provide guidance in the first place, they are in …..."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Sixth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Sixth sitting)

"I think the answer to the hon. Gentleman’s question under insolvency law is that the rights belong ultimately to the creditors and shareholders of the company that has been wound up, which is pretty bog standard insolvency law...."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Sixth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Sixth sitting)

"The administrators are employed to work on behalf of the creditors and shareholders, so they are serving their interests. It strikes me as relatively obvious that the rights over that intellectual property and those things that are relevant in this schedule still, either directly or indirectly through the administrators, lie …..."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Sixth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Sixth sitting)

"When you were last in government?..."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Sixth sitting)
Speech in Public Bill Committees - Tue 01 Dec 2020
National Security and Investment Bill (Sixth sitting)

"I am very sympathetic to the amendment tabled by the hon. Member for Ilford South. He refers to the Parliamentary Commission on Banking Standards, on which I sat. There is no question whatever that the bondholders of banks have a huge amount of influence on a bank—more so than the …..."
Mark Garnier - View Speech

View all Mark Garnier (Con - Wyre Forest) contributions to the debate on: National Security and Investment Bill (Sixth sitting)
Written Question
Cannabis: Medical Treatments
Thursday 30th January 2020

Asked by: Mark Garnier (Conservative - Wyre Forest)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone, (b) Savitex and (c) unlicensed cannabis-based products for medicinal use were issued by private healthcare specialist prescribers and dispensed in the community in October 2019.

Answered by Jo Churchill

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Written Question
Cannabis: Medical Treatments
Thursday 30th January 2020

Asked by: Mark Garnier (Conservative - Wyre Forest)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many prescriptions for unlicensed cannabis-based products for medicinal use were prescribed by the NHS and dispensed in the community in October 2019.

Answered by Jo Churchill

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Written Question
Cannabis: Medical Treatments
Thursday 30th January 2020

Asked by: Mark Garnier (Conservative - Wyre Forest)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone Savitex, (b) Epidiolex and (c) unlicensed cannabis-based products for medicinal use were dispensed by hospital pharmacies from November 2018 to October 2019.

Answered by Jo Churchill

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.